Mesa Laboratories (MLAB) Stock Price, News & Analysis

Company Overview

Mesa Laboratories, Inc. develops, manufactures, and distributes a diverse range of instruments and consumables designed to ensure quality control and safety in critical industrial, laboratory, and healthcare environments. The company’s product portfolio spans four primary business segments: BioScientific, Medical, Calibration, and Critical Care. Through these distinct operating units, Mesa offers biological indicator products for sterilization monitoring, anesthesia gas monitoring systems, precision temperature and pressure calibration equipment, and medical gas analysis solutions for hospitals and clinics.

Headquartered in Lakewood, Colorado, Mesa Laboratories was founded in the late 1960s and has grown through a combination of internal innovation and strategic acquisitions. Over the decades, the company has expanded its geographic footprint to serve customers in North America, Europe, Latin America, and the Asia-Pacific region. Mesa leverages an international network of manufacturing facilities, research and development centers, and distribution partners to support regulated industries that require rigorous safety and quality standards.

In its BioScientific segment, Mesa produces biological indicators and related consumables used primarily in healthcare and pharmaceutical sterilization processes. The Medical segment focuses on anesthesia gas monitoring and patient safety devices, while the Calibration segment supplies advanced temperature, pressure, and humidity calibration instruments for laboratory and industrial metrology applications. The Critical Care division delivers medical gas analyzers and verification systems that help hospitals meet stringent compliance and safety requirements.

Under the leadership of President and Chief Executive Officer Kenneth P. Roberts, Mesa Laboratories maintains a strong emphasis on product quality, regulatory compliance, and customer service. The company’s executive team brings extensive experience in life sciences, engineering, and global distribution. By investing in research and development and strengthening its international operations, Mesa Laboratories continues to address evolving market needs and support mission-critical processes across a wide array of end markets.

Key Stats

• Today's Range: $90.83 to $102.43
• 50-Day Range: $92.73 to $128.00
• 52-Week Range: $87.80 to $155.12
• Volume: 298,657 shs
• Average Volume: 54,750 shs
• Market Capitalization: $507.45 million
• P/E Ratio: N/A
• Dividend Yield: 0.69%
• Price Target: $130.00
• Consensus Rating: Hold

Mesa Laboratories Stock Analysis - MarketRank™

Mesa Laboratories scored higher than 61% of companies evaluated by MarketBeat, and ranked 369th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Mesa Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Mesa Laboratories has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.00%

Earnings Growth

Earnings for Mesa Laboratories are expected to grow by 9.00% in the coming year, from $8.00 to $8.72 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesa Laboratories is -251.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesa Laboratories is -251.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mesa Laboratories has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.54% of the float of Mesa Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Mesa Laboratories has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mesa Laboratories has recently increased by 0.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Mesa Laboratories has a dividend yield of 0.62%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Mesa Laboratories does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Mesa Laboratories will have a dividend payout ratio of 7.34% next year. This indicates that Mesa Laboratories will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.54% of the float of Mesa Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Mesa Laboratories has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mesa Laboratories has recently increased by 0.66%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.47

News Sentiment

Mesa Laboratories has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Mesa Laboratories this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mesa Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $296,507.00 in company stock.

Percentage Held by Insiders

Only 4.40% of the stock of Mesa Laboratories is held by insiders.

Percentage Held by Institutions

90.60% of the stock of Mesa Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MLAB Stock Analysis - Frequently Asked Questions

How have MLAB shares performed this year?

Mesa Laboratories' stock was trading at $131.87 at the beginning of 2025. Since then, MLAB stock has decreased by 29.5% and is now trading at $92.94.

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) released its quarterly earnings data on Tuesday, February, 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive trailing twelve-month return on equity of 27.51% and a negative net margin of 0.82%.

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' top institutional investors include Kings Path Partners LLC (0.06%). Insiders that own company stock include John Bradley Schmieder, Gary M Owens, Evan Guillemin, John Sakys, Shannon Hall and Brian David Archbold.
View institutional ownership trends.

How do I buy shares of Mesa Laboratories?

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesa Laboratories investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 2/04/2025
• Record date for 6/16 Dividend: 5/30/2025
• Ex-Dividend for 6/16 Dividend: 5/30/2025
• Dividend Payable: 6/16/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Electronic Equipment & Instruments
• Current Symbol: NASDAQ:MLAB
• CIK: 724004
• Web: www.mesalabs.com
• Phone: (303) 987-8000
• Fax: 303-987-8989
• Employees: 680
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $130.00
• High Stock Price Target: $160.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: +39.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.62
• P/E Growth: N/A
• Net Income: -$1.97 million
• Net Margins: -0.82%
• Pretax Margin: 2.47%
• Return on Equity: 27.51%
• Return on Assets: 9.78%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 0.63
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $240.98 million
• Price / Sales: 2.11
• Cash Flow: $11.02 per share
• Price / Cash Flow: 8.43
• Book Value: $29.42 per share
• Price / Book: 3.16

Miscellaneous

• Outstanding Shares: 5,460,000
• Free Float: 5,215,000
• Market Cap: $507.45 million
• Optionable: Not Optionable
• Beta: 0.86